New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
17:42 EDTCPHD, RHHBYCepheid says Roche patent suit will not have material adverse impact on results
Cepheid (CPHD) management stated that they have not had the opportunity to review the claim made by Roche (RHHBY) regarding a patent suit filed earlier; however management stated that it is their understanding that the patent has expired. Either way, the lawsuit will not have a material adverse impact on the company's results.
News For CPHD;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
17:35 EDTCPHDCepheid 'well positioned' to address Ebola
Subscribe for More Information
17:28 EDTCPHDCepheid sees Q4 adjusted EPS 2c-4c, may not compare to consensus (9c)
Subscribe for More Information
16:11 EDTCPHDCepheid sees FY14 adjusted EPS 11c-13c, may not compare to consensus (52c)
Subscribe for More Information
16:09 EDTCPHDCepheid reports Q3 EPS ex-items 6c, consensus (16c)
Subscribe for More Information
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:48 EDTCPHDCepheid recent weakness unjustified, says Canaccord
Subscribe for More Information
October 9, 2014
08:16 EDTCPHDCepheid price target lowered to $54 from $58 at Cowen
Cowen lowered its price target on Cepheid to $54 from $58 ahead of the company's Q3 results. The firm sees a modest upside to estimates and believes the company is well positioned for an acceleration of Commercial growth in 2015. Near term, however, Cowen sees only modest upside, but little risk, and maintains its Outperform rating on Cepheid shares.
07:46 EDTCPHDCepheid initiated with a Buy at Citigroup
Subscribe for More Information
October 8, 2014
11:31 EDTRHHBYFDA grants priority review for Genentech's Lucentis
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7M Americans. The FDA confirmed action date is February 6, 2015. The sBLA was submitted August 7 to address the unmet need for approved ocular medications for the treatment of diabetic retinopathy. If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients. The submission is based on results of the RISE and RIDE Phase III trials in which meaningful improvements in the disease were observed in a clinically significant proportion of diabetic retinopathy patients treated with Lucentis at two years compared to patients treated with sham injections. Benefits of Lucentis treatment were maintained during year three of treatment. The safety in the RISE and RIDE Phase III trials was consistent with previous studies.
10:55 EDTRHHBYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
07:19 EDTRHHBYCBI to hold a conference
Subscribe for More Information
07:18 EDTCPHDInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
October 6, 2014
06:02 EDTCPHDCepheid to benefit from stronger than normal flu season, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use